Pricing of biosimilars in Saudi Arabia

被引：3

作者：

Alhomaidan, Ali M.

Aljuffali, Ibrahim A. ^{[1
]}

Alnutaifi, Fahad S. ^{[2
]}

AL-Howaimel, Nasseruddeen A. ^{[2
]}

机构：

[1] Saudi Food & Drug Author, Drug Affairs, Riyadh, Saudi Arabia

[2] Saudi Food & Drug Author, Riyadh, Saudi Arabia

来源：

GABI JOURNAL-GENERICS AND BIOSIMILARS INITIATIVE JOURNAL | 2016年 / 5卷 / 01期

关键词：

Biosimilar; price; Saudi Arabia;

D O I：

10.5639/gabij.2016.0501.007

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Innovation in the pharmaceutical industry is expensive and risk must be rewarded. Some novel pharmaceuticals may be worth their high prices. Yet, high prices may hinder accessibility to novel products. It is paramount for pharmaceutical companies to demonstrate the value of their products in the face of increasingly budget-conscious stakeholders. This paper will provide background on the pricing of biosimilars in Saudi Arabia and explain the system used for pricing these products. Factors influencing pricing of pharmaceuticals in general as well as approaches to pharmaceuticals price control worldwide will be discussed.

引用

页码：27 / 29

页数：3

共 9 条

[1] Danzon PM, 2004, NBER FR HLTH POL RES, P1
[2] DICKSON M, 1992, CLIN THER, V14, P604
[3] Frank RG, 2004, J EC MANAG STRATEGY, V6
[4] Kraus L, 2004, MEDICATION MISADVENT
[5] Strategic pricing of new pharmaceuticals
Lu, ZJ
Comanor, WS
[J]. REVIEW OF ECONOMICS AND STATISTICS, 1998, 80 (01) : 108 - 118
[6] Saudi Food and Drug Authority, 2011, PHARM PRIC SYST 2011, P14
[7] Saudi Food and Drug Authority, 2011, EX REG LAW PHARM EST, P13
[8] The Saudi Food and Drug Authority, 2011, EX REG LAW PHARM EST
[9] World Health Organization, 1995, HLTH EC DRUGS DAP SE, V1

← 1 →